Lisinopril dihydrate: Single-Crystal X-Ray structure and physicochemical characterization of derived solid forms

Journal of Pharmaceutical Sciences

Volumn 102, Issue 10, 2013, Pages 3596-3603

  Sorrenti, Milena ^a   Catenacci, Laura ^a   Cruickshank, Dyanne L ^b   Caira, Mino R ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Amorphous; Calorimetry (DSC); Crystal structure; FT IR spectroscopy; Hydrogen bonding; Lisinopril dihydrate; Polymorphism; PXRD; Thermal analysis; Water in solids

Indexed keywords

LISINOPRIL;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; INFRARED SPECTROSCOPY; PHYSICAL CHEMISTRY; SOLID; TEMPERATURE; THERMOGRAVIMETRY; X RAY POWDER DIFFRACTION;

AMORPHOUS; CALORIMETRY (DSC); CRYSTAL STRUCTURE; FT-IR SPECTROSCOPY; HYDROGEN BONDING; LISINOPRIL DIHYDRATE; POLYMORPHISM; PXRD; THERMAL ANALYSIS; WATER IN SOLIDS;

CALORIMETRY, DIFFERENTIAL SCANNING; CRYSTALLIZATION; DEHYDRATION; DOSAGE FORMS; LISINOPRIL; SOLUBILITY; SOLVENTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TEMPERATURE; THERMOGRAVIMETRY; X-RAY DIFFRACTION; X-RAYS;

EID: 84883780856     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23660     Document Type: Article

References (28)

1. Simpson K, Jarvis B. 2000. Lisinopril: A review of its use in congestive heart failure. Drugs 59:1149-1167.
2. Langtry HD, Markham A. 1997. Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients. Drug Aging 10:131-166.
3. Raes A, Malfait F, Aken SV, France A, Donckerwolcke R, Walle JV 2007. Lisinopril in paediatric medicine: A retrospective chart review of long-term treatment in children. J Renin Angiotensin Aldosterone Syst 8:3-12.
4. Piepho RW. 2000. Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm 57:S3-S7.
5. Remko M. 2007. Acidity, lipophilicity, solubility, absorption, and polar surface area of some ACE inhibitors. Chem Pap 61:133-141.
6. Beermann B. 1988. Pharmacokinetics of lisinopril. Am J Med 85:25-30.
7. Natesh R, Schwager SLU, Sturrock ED, Acharya KR. 2003. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 421:551-554.
8. Saul SM, Duprez DA, Zhong W, Grandits GA, Cohn JN. 2012. Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: The DETECT study. J Hum Hypertens 27:362-367.
9. Stegbauer J, De-Hyung L, Seubert S, Ellrichmann G, Manzel A, Kvakan H, Muller DN, Gaupp S, Rump LC, Gold R, Linker RA. 2009. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. P Natl Acad Sci USA 106:14942-14947.
10. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK, Goldstein MJ, Bhat R, Raine CS, Sobel RA, Steinman L. 2009. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. P Natl Acad Sci USA 106:14948-14953.
11. Prasanth VV, Sirisha M, Sam TM, Kamalakkannan V, Rinku M. 2011. Mucoadhesive tablets of lisinopril for buccal drug delivery: Development and characterisation. Drug Invention Today 3:49-51.
12. Gannu R, Yamsani VV, Yamsani SK, Palem CR, Yamsani MR. 2009. Optimization of hydrogels for transdermal delivery of lisinopril by box-behnken statistical design. AAPS PharmSciTech 10:505-514.
13. Hilfiker R, Blatter F, Raumer MV. 2006. Relevance of solid-state properties for pharmaceutical products. In Polymorphism: In pharmaceutical industry; Hilfiker R, Ed. Germany: Wiley-VCH, Weinheim pp. 1-19.
14. Brittain HG. 2012. Polymorphism and solvatomorphism 2010. J Pharm Sci 101:464-484.
15. Lee AY, Erdemir D, Myerson AS. 2011. Crystal polymorphism in chemical process development. Annu Rev Chem Biomol 2:259-280.
16. Aaltonen J, Alles M, Mirza S, Koradia V, Gordon KC, Rantanen J. 2009. Solid form screening-A review. Eur J Pharm Biopharm 71:23-37.
17. Sorrenti M, Catenacci L, Bruni G, Luppi B, Bigucci F, Bettinetti G. 2012. Solid-state characterization of tacrine hydrochloride. J Pharm Biomed Anal 63:53-61.
18. Caira MR, Bettinetti G, Sorrenti M, Catenacci L. 2007. Relationships between structural and thermal properties of anhydrous and solvated crystalline forms of brodimoprim. J Pharm Sci 96:996-1007.
19. Bettinetti G, Caira MR, Sorrenti M, Catenacci L, Ghirardi M, Fábián L. 2004. Thermal studies of solvent exchange in isostructural solvates of a tetroxoprim-sulfametrole complex. J Therm Anal Calorim 77:695-708.
20. Fillip X, Borodi C, Oprean L, Filip C. 2009. Structural investigation of lisinopril by powder X-ray diffraction and solid-state NMR. J Phys Conf Ser 182:012007.
21. Fujii K, Uekusa H, Itoda N, Yonemochi E, Terada K 2012. Mechanism of dehydration-hydration processes of lisinopril dihydrate investigated by ab initio powder X-ray diffraction analysis. Cryst Growth Des 12:6165-6172.
22. David R Lide CRC handbook of chemistry and physics. 2003. 84th ed. CRC Press Inc. Boca Raton
23. Bruker (2007). SAINT Bruker AXS Inc., Madison, Wisconsin, USA Version 7.60a. .
24. Sheldrick GM. 2008. A short history of SHELX. Acta Crystallogr A64:112-122.
25. Spek AL. 2003. Single-crystal structure validation with the program PLATON. J Appl Crystallogr 36:7-13.
26. General Chapter (711). 2012. The dissolution procedure: Development and validation. In The United States Pharmacopoeia 35 - National Formulary 30. United States pharmacopeial Convention, Inc., Rockville, Maryland
27. Etter MC, MacDonald JC, Bernstein J. 1990. Graph-set analysis of hydrogen bnd patterns in organic crystals. Acta Crystallogr B46:256-262.
28. Brown J, AstraZeneca AB. 2002. Monohydrate lisinopril. Patent US6465615B1.